Moleculin Biotech, Inc. filings document regulatory disclosures for a Delaware clinical-stage pharmaceutical company focused on drug development and commercialization. Recent Form 8-K reports cover Regulation FD releases, investor presentations, financial results, clinical and preclinical updates for Annamycin, and intellectual-property matters involving liposomal Annamycin.
The filing record also includes capital-structure and governance disclosures tied to warrant exercise inducement arrangements, warrant-related share issuance, and stockholder voting matters. Definitive proxy materials and voting results describe special-meeting proposals, including Nasdaq-related approval for warrant shares and charter-related governance items, while exhibit filings attach press releases, presentation materials, and other public-company disclosures.
Moleculin Biotech, Inc. (MBRX) furnished a new corporate presentation as an exhibit to a current report. The presentation, identified as Exhibit 99.1, is being used for the company’s corporate communications and is posted on its website. The company states that this material is being furnished under Regulation FD and will not be treated as "filed" for purposes of the Securities Exchange Act of 1934 or automatically incorporated into other SEC filings unless specifically referenced. This is primarily a disclosure and investor‑information update rather than an operational or financial event.
Moleculin Biotech, Inc. reported that Nasdaq has issued a determination to delist its common stock after the company failed to regain compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity or specified alternative criteria.
Nasdaq previously gave the company until November 19, 2025 to regain compliance, but a letter dated November 20, 2025 states that the company remains non-compliant.
Unless Moleculin requests a hearing before a Nasdaq panel by November 28, 2025, its securities are scheduled to be delisted on December 2, 2025. The company intends to appeal this determination under Nasdaq’s procedures, and its common stock is expected to continue trading on The Nasdaq Capital Market under the symbol “MBRX” while the appeal is pending.
Moleculin Biotech (MBRX) filed a Form 4 for EVP & CFO Jonathan P. Foster reporting equity awards dated 11/12/2025. The filing lists a stock option for 600,000 shares at an exercise price of $0.49, expiring 11/12/2035, vesting in four equal annual installments beginning on the first anniversary. It also reports 400,000 performance-based RSUs that vest in 20% increments upon achievement of specified clinical milestones; 100% vest upon a change of control as defined in the 2024 Stock Plan. Following these transactions, derivative securities beneficially owned were 2,017,695, held directly.
Moleculin Biotech (MBRX) disclosed insider equity awards to its CEO and President on 11/12/2025. The filing reports a stock option grant for 830,000 shares at an exercise price of $0.49, vesting in four equal annual installments beginning on the first anniversary of the grant, subject to continued service.
The CEO also received 750,000 performance-based restricted stock units, each representing one share. These RSUs vest in 20% increments upon achievement of specified clinical milestones, and 100% vest upon a change of control as defined in the 2024 Stock Plan. Following these awards, the form shows 3,960,731 derivative securities beneficially owned.
Moleculin Biotech (MBRX) reported a director’s stock option grant on a Form 4. The filing shows 150,000 stock options with an exercise price of $0.49, granted on 11/12/2025. These options vest on 11/12/2026, subject to continued Board service, and expire on 11/12/2035.
Following this transaction, the filing lists 164,001 derivative securities beneficially owned, held in direct ownership. The options were issued in connection with the reporting person’s Board of Director service.
Moleculin Biotech (MBRX) reported a director’s grant of 150,000 stock options (Transaction Code A) at an exercise price of $0.49 on November 12, 2025.
The options vest on November 12, 2026, subject to continued Board service, and expire on November 12, 2035. Following this grant, the reporting person beneficially owned 165,336 derivative securities, held directly. The filing notes the options were issued in connection with Board service.
Moleculin Biotech (MBRX) reported a director’s grant of stock options. The filing shows 150,000 stock options (right to buy) at an exercise price of $0.49 per share on 11/12/2025, coded “A” for award. These options vest on 11/12/2026 and expire on 11/12/2035, issued in connection with Board service. Following this transaction, the director beneficially owned 165,169 derivative securities, held directly.
Moleculin Biotech reported a wider quarterly loss and a new stockholders’ deficit. For Q3 2025, net loss was $25,399,000 as operating expenses fell to $5,906,000 but were overshadowed by a $20,609,000 loss on issuance of warrant liabilities. Year‑to‑date net loss reached $49,112,000.
Cash and cash equivalents were $6,703,000 as of September 30, 2025, up from $4,278,000 at year‑end, aided by warrant exercises and equity transactions. Total assets were $20,353,000. A new long‑term warrant liability of $41,333,000 and accumulated losses drove stockholders’ equity to a deficit of $26,920,000.
The company disclosed substantial doubt about its ability to continue as a going concern, noting current cash is not sufficient for at least one year. It received Nasdaq notices related to stockholders’ equity and bid price, with an extension to November 19, 2025 for equity compliance and a bid‑price compliance period until December 24, 2025. In 2025, Moleculin completed multiple financings, including a June offering with Series E warrants ($0.37 exercise price) and an August inducement generating $6.0 million and issuing Series F warrants ($0.55 exercise price). A July 2025 ATM program authorizes up to $6.5 million.
Moleculin Biotech reported progress in its pivotal Phase 2B/3 MIRACLE study of Annamycin plus cytarabine for adult AML patients who are refractory to or relapsed after induction therapy. As of November 4, 2025, 60% of the target number of subjects for the first planned interim unblinding had consented.
The first interim unblinding targets 45 subjects. The company expects to complete treatment of these first 45 subjects in Q1 2026, with the initial unblinding of data thereafter. Identification and recruitment are ongoing. The update was announced via press release furnished as Exhibit 99.1.
Moleculin Biotech, Inc. (MBRX) reported that it entered into a research and material transfer agreement with the University of North Carolina at Chapel Hill to support investigator‑initiated preclinical research evaluating Annamycin for the treatment of pancreatic cancer. The company furnished this update via an 8‑K, noting that the related press release is attached as Exhibit 99.1.
The disclosure is provided under a furnished information item and is not deemed filed. This agreement enables UNC investigators to conduct preclinical studies of Annamycin in pancreatic cancer models, reflecting continued nonclinical development activity around Moleculin’s anthracycline candidate.